RYTM Stock Analysis: Buy, Sell, or Hold?
RYTM - Rhythm Pharmaceuticals, Inc. Common Stock
$107.49
-0.91 (-0.84%)
▼
5d:
-3.75%
30d:
+25.41%
90d:
+27.37%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
21d
Get Alerted When RYTM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RYTM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RYTM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RYTM is currently trading at $107.49, which is considered slightly high relative to its 30-day fair value range of $90.35 to $112.15.
Technical Outlook: Technically, RYTM is in a uptrend. The price is currently testing key support at $104.55. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $139.73 (+30.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RYTM is in a uptrend. The price is currently testing key support at $104.55. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $139.73 (+30.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$90.35 -
$112.15
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.0% below Wall St target ($139.73)
Trading Range Analysis
30-Day Trading Range
$90.35 -
$112.15
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$8.75
(8.1%)
Support & Resistance Levels
Support Level
$104.55
Resistance Level
$115.92
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-156.83
Wall Street Target
$139.73
(+30.0%)
Revenue Growth (YoY)
83.8%
Profit Margin
-93.3%
Share & Embed Analysis
Last updated: July 13, 2026 6:01 PM ET
Data refreshes hourly during market hours. Next update: 7:01 PM
Data refreshes hourly during market hours. Next update: 7:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RYTM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Paul German
SELL
5614 shares
2026-03-04
Hunter C Smith
SELL
4385 shares
2026-02-19
Hunter C Smith
SELL
3569 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
Advanced RYTM Option Strategies
Professional options setups generated by AI based on today's RYTM price and gamma walls.
